A new study may help clarify why some people infected with HIV are better able to control the virus. It may also pinpoint a target for treatment during early HIV infection aimed at increasing the supply of certain immune cells in the gut.
Early treatment with antiretroviral therapy reduced the production of latently infected T-cells, a barrier to curing infection
William A. Rutala, PhD, MPH, was honored by the UNC Gillings School of Global Public Health with this prestigious award for alumni at a ceremony preceding the annual Fred T. Foard Jr. Memorial Lecture on April 17.
New research finds that early weaning – stopping breastfeeding before six months – is of little, if any, protective value against HIV transmission nor is it safe for infant survival.
CHAPEL HILL -- A team of researchers at the University of North Carolina at Chapel Hill have successfully flushed latent HIV infection from hiding, with a drug used to treat certain types of lymphoma.
More than 8,000 women participated in the NIH-funded study, which was conducted in part at UNC. The vaccine was partially effective at preventing herpes simplex virus type 1 (HSV-1), but did not protect women from herpes simplex virus type 2 (HSV-2).
First results from ongoing Phase III trial show malaria vaccine candidate, RTS,S* reduces the risk of malaria by half in African children aged 5 to 17 months
The University of North Carolina at Chapel Hill enrolled 1,600 children at the study site in Lilongwe, Malawi.
This is the first study to demonstrate active replication of HIV virus in a cell type other than immune T cells and which may help to predict patients at greatest risk for HIV dementia.
A new study led by researchers at the University of North Carolina at Chapel Hill finds that there may be a limit to how early the therapy, known as HAART, should start.
The UNC Center for AIDS Research (CFAR) plays an active role in education and outreach, and provides developmental grant awards to support new ideas and new investigators in HIV/AIDS research.
July 13, 2011 – A new study by investigators from the University of North Carolina at Chapel Hill School of Medicine has confirmed the existence of a “trial effect” in clinical trials for treatment of HIV and also shows that effect has diminished over time.
July 11, 2011 -- Researchers at the University of North Carolina at Chapel Hill have been awarded a $32 million, five-year federal grant to develop ways to cure people with HIV by purging the virus hiding in the immune systems of patients taking antiretroviral therapy. Tackling this latent virus is considered key to a cure for AIDS.
July 8, 2011 – Adaora Adimora, MD, MPH, professor of medicine in the Division of Infectious Diseases in the Department of Medicine at UNC, has been appointed to the Advisory Council of the National Institute of Allergy and Infectious Diseases.
In comparing data from experiments with Hepatitis A and Hepatitis C, the research team found that Hepatitis A virus, which causes only acute, self-limited disease, is more efficient at inhibiting the host’s interferon response, and that the virus can actually linger in the body for almost a year.
UNC researchers have been awarded the prestigious Charles C. Shepard Science Award in the category of Prevention and Control by the Centers for Disease Control and Prevention for their paper titled, “Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.”